Quartz·1 min read·medium
AbbVie beat profit estimates but cut its forecast — and the stock sank
✦AI Summary
AbbVie reported strong second-quarter immunology sales that exceeded analyst expectations. However, the company's stock price fell after it lowered its full-year adjusted earnings forecast by 14 cents per share.
The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share
businesseconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in